tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amgen’s PRMT5 drug shows 5 partial responses from 31 patients, STATnews reports

Amgen (AMGN) on Friday presented preliminary results from its first study on a cancer drug target called PRMT5 that selectively blocks the enzyme in cancer cells, showing five partial responses from 31 evaluable patients, STATnews’ Adam Feuerstein reports. Previously, a rival PRMT5 inhibitor being developed by Mirati Therapeutics (MRTX) factored into Bristol Myers Squibb’s (BMY) decision to acquire the company.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

1